Traders should watch for upcoming earnings, regulatory decisions, or trial readouts that may have prompted this coordinated selling. Absent public catalysts, the pattern suggests executives are reducing exposure, potentially anticipating downside risk. Monitor for Form 144 filings or further open-market activity.
Price Chart
Executive Summary
Travere Therapeutics insiders executed a significant cluster of open-market sales totaling $2.1 million over seven days, led by the General Counsel selling over $1.75 million of shares. The CFO and CMO also sold smaller amounts, while non-cash transactions (grants, exercises) were routine. This wave of selling by multiple executives signals potential lack of confidence ahead of key catalysts.
Key Financial Metrics
Key Facts
- General Counsel Elizabeth Reed sold 42,726 shares for $1.76 million in open-market transactions on April 14–15, 2026.
- CFO Christopher Cline and CMO Jula Inrig each sold approximately $45,000–$47,000 in stock, contributing to a total of $2.1 million in insider sales over 7 days.
- Non-cash transactions included stock grants and option exercises totaling $190,800, which are standard and not economically significant.
- Total open-market sales represent ~0.05% of the $3.9B market cap, but concentration among C-suite executives amplifies the signal.
- Sales occurred in a tight window across multiple senior executives, suggesting coordinated action rather than routine pre-arranged plans.
Financial Impact
$2.1 million in net open-market sales by insiders over 7 days
Risk Factors
- Downside risk if near-term catalysts (e.g., FDA decisions, trial data) disappoint
- Erosion of market confidence due to concentrated insider selling
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TVTX-1776304055994 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 9, 2026 12w ago | 8-K | $56.59 $61.32 | ▲ +8.36% | ▲ +5.93% | $56.93 (+0.60%) |
Jun 16, 2026 15w ago | Insider Cluster | $54.14 $55.28 | ▲ +2.11% | ▲ +0.79% | $56.93 (+5.15%) |
Jun 16, 2026 15w ago | 8-K | $54.14 $55.28 | ▲ +2.11% | ▲ +0.79% | $56.93 (+5.15%) |
Jun 12, 2026 16w ago | 144 | $52.04 $56.59 | ▲ +8.74% | ▲ +6.96% | $56.93 (+9.40%) |
Jun 2, 2026 17w ago | 8-K | $42.96 $56.34 | ▲ +31.15% | ▲ +32.71% | $56.93 (+32.52%) |
May 15, 2026 20w ago | 144 | $42.59 $53.80 | ▲ +26.32% | ▲ +24.20% | $56.93 (+33.67%) |
May 5, 2026 21w ago | 144 | $44.76 $45.20 | ▲ +0.98% | ▼ −1.80% | $56.93 (+27.19%) |
May 4, 2026 21w ago | 144 | $44.80 $42.96 | ▼ −4.11% | ▼ −9.06% | $56.93 (+27.08%) |
May 1, 2026 22w ago | Insider Cluster | $44.12 $45.04 | ▼ −2.09% | ▲ +3.20% | $56.93 (−29.03%) |
Apr 15, 2026 24w ago | 144 | $40.95 $42.84 | ▲ +4.62% | ▼ −1.43% | $56.93 (+39.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access